Enterprise Value (based on primary fundings)

Company Description

Developer of a new class medicines intended to treat inherited genetic disorders, hemophilic and blood factors and oncology. The company's mRNA technology platform accelerates drug discovery and speeds early development for mRNA-based vaccines and therapies spanning several therapeutic areas, as well as produces human proteins and antibodies inside patient cells, enabling clinicians to address currently undruggable targets and offer an alternative to existing drug modalities for a wide range of diseases and conditions.

Company Info

Website: www.modernatx.com

Industry: BioTech

Funding to Date: $1.84B

Last Round Est. Valuation: $18.05B

Management Team
  • Stephen Hoge MD - President
  • Lorence Kim MD - Chief Financial Officer
  • Annie Drapeau - Chief Human Resources Officer
  • Melissa Moore Ph.D - Chief Scientific Officer
  • Marcello Damiani - Chief Digital Officer
  • Kenneth Chien - Co-Founder
  • Stephen Bancel - CEO
  • Juan Andres - Chief Technical Operations and Quality Officer
  • Said Francis - Senior Director of Business Development

Moderna News

Article
2018-12-04

WSJ - Biotech company Moderna has dropped an underwriter from its planned initial public offering because that firm made “unauthorized communications” about the offering, Moderna disclosed in a securities filing.

View More

Important Notice

You are now leaving the SharesPost 100 Fund area of the SharesPost website and proceeding to either a) SharesPost Inc. and its affiliates including SharesPost Financial Corporation, a separate company registered as a broker/dealer with the Securities and Exchange Commission and member of FINRA/SIPC, and SharesPost Investments Management, LLC, a registered investment advisor, or b) to another third party, including UMB Fund Services, Inc. and Foreside Fund Services, LLC, both SharesPost 100 Fund service providers.

go back continue

To view this content, please sign up or login.

Sign Up  Log In

Close